Glaukos Corporation Common Stock (GKOS)

FairStock Score: 26/100 — RISKY

Key Financials

Strengths

• Generates $6 million in annual free cash flow (0.1% yield on market cap)
• Conservative balance sheet with debt-to-equity of just 0.16, providing financial flexibility
• Altman Z-Score of 16.6 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 35.7% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Glaukos Corporation Common Stock is a small-cap healthcare company valued at $7.1 billion. Revenue stands at $551 million, though the company is currently unprofitable. From a quality standpoint, Glaukos shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and Altman Z-Score of 16.6 confirms fortress-level solvency. Growth dynamics show revenue growing at 35.7% and profit growth of -298.0%. Our composite FairStock Score of 26/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Glaukos's 36% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $6 million in annual free cash flow (0.1% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer